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Abstract
Aims: Synapses represent a major pathological target across a broad range of
neurodegenerative conditions. Recent studies addressing molecular mechanisms
regulating synaptic vulnerability and degeneration have relied heavily on inver-
tebrate and mouse models. Whether similar molecular neuropathological
changes underpin synaptic breakdown in large animal models and in human
patients with neurodegenerative disease remains unclear. We therefore investi-
gated whether molecular regulators of synaptic pathophysiology, previously
identified in Drosophila and mouse models, are similarly present and modified
in the brain of sheep with CLN5 Batten disease. Methods: Gross neuropatho-
logical analysis of CLN5 Batten disease sheep and controls was used alongside
postmortem MRI imaging to identify affected brain regions. Synaptosome
preparations were then generated and quantitative fluorescent Western blotting
used to determine and compare levels of synaptic proteins. Results: The cortex
was particularly affected by regional neurodegeneration and synaptic loss in
CLN5 sheep, whilst the cerebellum was relatively spared. Quantitative assess-
ment of the protein content of synaptosome preparations revealed significant
changes in levels of seven out of eight synaptic neurodegeneration proteins
investigated in the motor cortex, but not cerebellum, of CLN5 sheep (a-synu-
clein, CSP-a, neurofascin, ROCK2, calretinin, SIRT2, and UBR4). Conclusions:
Synaptic pathology is a robust correlate of region-specific neurodegeneration in
the brain of CLN5 sheep, driven by molecular pathways similar to those
reported in Drosophila and rodent models. Thus, large animal models, such as
sheep, represent ideal translational systems to develop and test therapeutics
aimed at delaying or halting synaptic pathology for a range of human neurode-
generative conditions.
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Introduction
Progressive neurological conditions such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and
some lysosomal storage disorders, including the neuronal
ceroid lipofuscinoses (NCLs; Batten disease; http://
www.ucl.ac.uk/ncl (Kousi et al. 2012)), are a genetically,
pathologically and clinically heterogeneous group of dis-
eases. Recent molecular and pathological evidence points
to a shared feature of many such diseases: a critical vul-
nerability of synapses in affected brain regions (Wishart
et al. 2006; Gillingwater and Wishart 2013). Thus, dys-
function and breakdown of synaptic connections is often
one of the best neuropathological correlates of a
patient’s functional decline. For example, the onset of
synaptic pathology strongly correlates with the onset of
neurological symptoms in both Alzheimer’s disease
(Davies et al. 1987; Terry et al. 1991) and Huntington’s
disease (Li et al. 2003). Similarly, synaptic dysfunction
and degeneration is an early event occurring in affected
brain regions during many genetically distinct forms of
Batten disease (NCL) (Virmani et al. 2005; Luiro et al.
2006; Partanen et al. 2008; Kielar et al. 2009; Koch et al.
2011).
That synaptic pathology represents a common cellu-
lar event across numerous neurological disorders raises
the possibility of shared molecular mechanisms regu-
lating synaptic pathophysiology that are independent
of the neurodegenerative “trigger”. This hypothesis is
supported by several lines of experimental evidence.
For example, a spontaneous genetic mutation that
robustly delays synaptic degeneration (known as WldS)
can ameliorate neurodegeneration across a range of
conditions, including some forms of motor neuron
disease (Ferri et al. 2003), Parkinson’s disease (Sajadi
et al. 2004) and following global cerebral ischemia
(Gillingwater et al. 2004) or traumatic brain injury
(Gillingwater et al. 2006). Furthermore, at the molecu-
lar level, a number of individual synaptic proteins that
can modulate synaptic vulnerability and degeneration
in response to a variety of pathological stimuli have
recently been identified, including CSP alpha/DNAJC5
(Fernandez-Chacon et al. 2004; Garcıa-Junco-Clemente
et al. 2010; Noskova et al. 2011; Wishart et al. 2012;
Kashyap et al. 2014).
Our growing awareness of the mechanisms underly-
ing synaptic pathophysiology raises the possibility that
targeted synapto-protective therapies could be devel-
oped for the treatment of a variety of neurodegenera-
tive conditions. One major issue facing such
translational neurodegeneration research, however, is
the current overreliance on small animal models, such
as mice, that do not fully replicate many size- and
age-related aspects of the human nervous system
(Aigner et al. 2010; Morton and Howland 2013; Pou-
ladi et al. 2013; Dolezalova et al. 2014). The growing
availability of large animal models of neurodegenera-
tion, including sheep and pigs, offers one solution to
this problem, but it has yet to be established if the
mechanisms underlying synaptic pathophysiology that
have been identified in rodent and Drosophila models
are conserved in larger species.
Although genetically modified large animal models
of neurodegeneration are becoming more common-
place (Aigner et al. 2010; Morton and Howland 2013;
Dolezalova et al. 2014), there are also a number of
human neurodegenerative conditions where there is an
equivalent endogenous condition in a large animal
species. Batten disease is exceptional in this regard,
with research on naturally occurring large animal
models having led the way for five decades (Palmer
et al. 2011; Bond et al. 2013). Batten disease often
refers to a group of fatal neurodegenerative disorders
that mainly begin in childhood, representing the most
common group of childhood neurodegenerative dis-
eases, also collectively known as the neuronal ceroid
lipofuscinoses (NCLs) (Palmer et al. 2011; Bond et al.
2013). The sheep used in this study have a late infan-
tile variant CLN5 form of Batten disease. A number
of naturally occurring large animal forms of CLN5
Batten disease have been described, including two in
dogs (Melville et al. 2005; Gilliam et al. 2015), a form
in cattle (Houweling et al. 2006), and this well-devel-
oped form in New Zealand Borderdale sheep, which
have a c.571 + 1G>A splice site mutation in the CLN5
gene that causes disease (Jolly et al. 2002; Frugier
et al. 2008; Palmer et al. 2015).This mutation leads to
the loss of a 50 splice donor site between exon and
intron 3, resulting in excision of exon 3, a down-
stream frame shift and premature termination of
translation.
The major neuropathological features of CLN5 Batten
sheep closely mirror those of human CLN5 Batten disease
(a variant late-infantile Batten disease) caused by muta-
tions in the human CLN5 gene (Jolly et al. 2002; Frugier
et al. 2008; Palmer et al. 2015; Perentos et al. 2015). As
with many other forms of Batten disease, mutations in
the CLN5 gene have been shown to trigger early synaptic
pathology in the affected brain regions of mouse models
(von Schantz et al. 2009). We therefore set out to estab-
lish the feasibility of isolating synapses from the brain of
sheep with Batten disease in order to test whether known
molecular regulators of synaptic pathophysiology, previ-
ously identified in Drosophila and mouse models, are sim-
ilarly present and modified in the brain of sheep with
CLN5 Batten disease.
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Materials and Methods
Ethics statement
All animal procedures were carried out in accordance
with NIH guidelines and the New Zealand Animal Wel-
fare Act 1999 as approved by the Lincoln University Ani-
mal Ethics committee. Experimental procedures
performed in Cambridge were conducted in accordance
with the UK Animals (Scientific Procedures) Act 1986
and were approved by a University of Cambridge internal
ethical review board.
Animals
CLN5 sheep and heterozygous controls were born, raised,
and diagnosed from a flock of Borderdale sheep at Lin-
coln University (New Zealand) (Frugier et al. 2008; Pal-
mer et al. 2015). Heterozygous sheep were chosen as
controls because they do not develop any signs of disease
(based on clinical and postmortem observations of over a
hundred breeding ewes kept for an average of seven
years) but otherwise share their genetic background with
the homozygous sheep.
Sheep for gross neuropathological analyses were sacri-
ficed at the Lincoln University by exsanguination, and the
head perfusion-fixed via one of the carotid arteries with
10% formalin in 0.9% NaCl, pH7.4, after the blood was
first cleared with 0.9% NaCl (37°C). The brains were
bisected at the sagittal midline, fixed for a further 7 days
in 10% formalin, equilibrated in cryoprotective solution
(10% ethylene glycol, 20% sucrose in 0.9% NaCl), and
stored frozen at 80°C until they were sectioned.
Cohorts of heterozygous controls and presymptomatic
CLN5 sheep for MRI and molecular analyses were
shipped by air to the University of Cambridge (U.K.)
where they were housed in a barn with windows and sup-
plementary additional artificial light (from 6 am to
6 pm). All animals had free access to hay feed and water,
with additional pellet supplements provided every morn-
ing. Sheep were sacrificed following an i.v. overdose of
barbiturate-based anesthetic. Selected brain regions were
flash-frozen by submersion in liquid nitrogen before
being stored at 80°C until ready for shipping to Edin-
burgh. Postmortem delay from death to samples being
frozen was 15–20 min per animal. Tissue was obtained
from eight 20–24-month-old CLN5 female sheep, and five
heterozygous controls, four females and one castrated
male, of comparable age.
Young adult C57BL/6 (wild-type) mice were obtained
from in-house breeding stocks at the University of Edin-
burgh. Mice were killed by inhalation overdose of Isoflu-
rane, in accordance with the guidance and rules of the
UK Home Office. Brains were immediately dissected and
used for synaptosome preparation.
Gross pathology
Cryopreserved perfusion fixed frozen brain hemispheres
were serially sectioned at 50 lm on a sliding microtome
(Microm, Germany) and the sections mounted on slides,
stained with Nissl, then coverslipped (Oswald et al.
2005). Images were captured using a Nikon Eclipse 50i
model microscope and cortical thicknesses in three ani-
mals of each genotype at 24 months of age were deter-
mined using NIS-Elements Software (Nikon Instruments
Inc., Melville, NY). At least 25 measurements were
made for each animal from the pial surface to the white
matter (cortical layers I–VI) in the primary motor cor-
tex and from the pial surface to the granular boundary
with the white matter in the anterior lobe of the
cerebellum.
Magnetic resonance imaging
To compare the morphology of CLN5 Batten disease
sheep against heterogeneous gene carriers, we scanned
each using magnetic resonance imaging (MRI). A 4.7T
Bruker BioSpec 47/40 was used to image brains from
sheep that had been euthanized and then perfusion fixed
in 4% paraformaldehyde in saline. Heads were trimmed
to remove the jaw and orbits but the brains were not
removed from the cranium to preserve the cortical
surface.
Brains were imaged using a rapid acquisition with
relaxation enhancement protocol with a field of view of
128 9 85.2 9 66.6 mm3 with a matrix of 384 9 256 9
200 with twofold anti-aliasing in all three directions to
provide an isotropic resolution of 333 lm. The repetition
time was 1.2 s with an affective echo time of 50 ms with
an echo train length of five and a bandwidth of 50 kHz
with a total scan time of 13.5 h per brain. For com-
parison, reconstructed images were rigidly registered
together, using SPM12 (Wellcome Trust Centre for
Neuroimaging, University College London) and the
SPMMouse toolbox (Sawiak et al. 2013).
Synaptosome preparation
Synaptosomes were prepared from fresh mouse whole
brain tissue and flash-frozen sheep brain tissue. Frozen
samples were briefly incubated in a water bath at 37°C to
ensure they were completely thawed before proceeding.
Due to the size of the sheep brain regions and the neces-
sity to use relatively small, and therefore heterogeneous,
samples for the efficient preparation of synaptosomes,
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two independent synaptosome samples were prepared and
analyzed for each animal.
Brain samples were homogenized in ice-cold sucrose
buffer (0.32M sucrose, 5mM Tris-HCl, 1mM EDTA, pH
7.4), using a glass plunger and centrifuged for 10 min at
900g and 4°C. The supernatant was collected and the pel-
let resuspended in sucrose buffer and centrifuged as
before. The supernatant was combined with the super-
natant from the initial spin and centrifuged at 20,000g for
15 min to pellet out crude synaptosomes. The super-
natant was discarded and the synaptosomes stored at
80°C until required.
Quantitative fluorescent Western blot
analysis
Quantitative Western blotting was used to determine rel-
ative protein levels, as previously described (Roche et al.
2014; Wishart et al. 2014). Briefly, all proteins extracted
from synaptosome and whole tissue preparations were
homogenized and extracted in RIPA buffer (Thermo-
Scientific, Paisley, U.K.) with a protease inhibitor cocktail
(ThermoScientific) and the protein concentration deter-
mined by BCA assay (ThermoScientific). The extracted
protein was then separated using SDS–polyacrylamide
gel electrophoresis (Precast NuPage 4–12% Bis-Tris gra-
dient gels [Invitrogen, Paisley, U.K.]) before being trans-
ferred to PVDF membrane, using the iBlot semi-dry
blotting system (Invitrogen). PVDF membranes were
then exposed to standard blocking solution (LI-COR,
Biosciences, Cambridge, U.K.) for 30 min at room tem-
perature. Quantitative fluorescent Western blots were
performed using primary antibodies against a-synuclein
(1:1000, Santa Cruz), b-actin (1:5000, Abcam), calretinin
(1:1000, Swant), CSP-a (1:1000, Abcam), CNPase (1:250,
Abcam), HDAC2 (1:250, Active Motif), neurofascin
(1:5000, Abcam), ROCK2 (1:250, Abcam), SIRT2 (1:500,
Abcam), SV2 (1:5000, Development Studies Hybridoma
Bank), UBR4 (1:1000, Abcam). All primary antibodies
were diluted in blocking solution with 0.1% Tween-20
(Sigma, Dorset, U.K.) and were applied overnight at
4°C. Following several washes in PBS, Odyssey secondary
antibodies (goat anti-rabbit IRDye 680 or donkey anti-
mouse IRDye 800, LI-COR Biosciences) were diluted in
blocking solution with 0.1% Tween-20 (Sigma) and
added to membranes for 1 h (room temperature). Blots
were washed again in PBS (3 9 10 min washes) before
being dried and imaged, using an Odyssey Infrared
Imaging System (LI-COR, Biosciences). Each blot was
scanned independently and the intensity of each fluores-
cent band was measured in triplicate, in order to mini-
mize user variability, using the Image Studio software
(LI-COR, Biosciences).
Statistical analysis
Data were collected into Microsoft Excel spreadsheets and
analyzed, using GraphPad Prism software. All data are
reported as mean  SEM. Individual statistical tests used
are detailed in figure legends. Statistical significance was
considered to be P ≤ 0.05 for all analyses. Figures were
created using Adobe Photoshop.
Results
Identification of brain regions that undergo
neurodegeneration in CLN5 sheep brain
Regional variations in neurodegeneration in CLN5 Bat-
ten disease sheep brain were initially investigated to
identify an area of the brain subject to substantial neu-
rodegeneration at the late stage disease, as well as an
area where there is very little, if any, neurodegeneration.
Gross neuropathological changes were analyzed in com-
plete sagittal sections of late stage ovine CLN5 Batten
disease. Atrophy of all cortical regions was obvious
macroscopically at 24 months, however, both subcortical
nuclei and the cerebellum of CLN5 brains retained a
normal appearance (Fig. 1). Nissl-stained sections were
analyzed for cortical thickness and cytoarchitectural
changes in different brain regions. Cortical atrophy was
most severe, in descending order, in the primary visual,
parieto-occipital and motor cortex regions of the CLN5
sheep brain, with progressive thinning of the neuronal
layers, particularly the upper layers (II–III), and by
24 months of age few cortical neurons were left (Fig. 2).
At this age, the cortical thickness of the primary motor
area of CLN5 animals was only 56% of that observed in
normal controls (Table 1; Fig. 2). In contrast, no dis-
ease-related cytoarchitectural differences were apparent in
the cerebellum between control and CLN5 animals
(Fig. 1), and there was no detectable difference in cere-
bellar cortical thicknesses (Table 1).
Neuropathological changes in CLN5 sheep were also
studied by MRI of perfusion fixed brains in situ. Repre-
sentative MRI images of control (heterozygous) and
CLN5 Batten disease sheep are shown in Figure 3. Com-
pared to brains of control sheep, brains from CLN5 Bat-
ten disease sheep had the same striking reduction in
neocortical volume, with relative sparing of subcortical
structures and the cerebellum.
Taken together, these neuropathological studies con-
firmed that CLN5 deficiency in sheep affects brain areas
in a differential manner, with the cerebellum being rela-
tively spared from disease-related neurodegeneration and
the cortex being severely affected. Since the motor cortex
was grossly degenerate and easily accessible, tissue was
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harvested from this region for subsequent biochemical
comparison with cerebellar tissue.
Synapse loss in affected regions of CLN5
Batten sheep brain
Given that synapse loss has been identified as a feature of
CLN5 pathology in mouse models (von Schantz et al.
2009), we wanted to verify whether synapses were also
being targeted in the CLN5 Batten sheep. Quantitative
fluorescent Western blotting was initially used to measure
the synaptic protein SV2 in whole tissue samples from a
brain region unaffected by neurodegeneration (the cere-
bellum). SV2 levels remained unaltered in the cerebellum
of CLN5 sheep compared to controls, confirming the low
vulnerability of synapses in this specific region of the
brain (Fig. 4). In contrast, SV2 levels were significantly
reduced in a region where neurodegeneration was signifi-
cant (the motor cortex) in CLN5 Batten sheep, indicative
of a substantial loss of synapses (Fig. 4).
Isolation of enriched synaptic preparations
(synaptosomes) from CLN5 Batten sheep
brain
Next, we wanted to establish whether we could generate
tissue samples enriched with synaptic material (synapto-
somes) from the brains of CLN5 Batten sheep, with a
similar efficiency and reproducibility previously found
when using mouse tissue (c.f. Wishart et al. 2012; 2014).
We adapted the subcellular fractionation protocol previ-
ously used for fresh mouse brain for frozen brain samples
from the sheep. Larger volumes of buffer and a higher
number of passages were required to homogenize sheep
tissue when compared to the mouse whole brain. Fluores-
cent Western blotting on synaptosome preparations con-
firmed a robust enrichment of a marker synaptic protein,
SV2, and almost complete exclusion of a nuclear protein,
HDAC2, in synaptosome preparations from both control
and CLN5 sheep brains (Fig. 5). Similarly, we found no
major differences between synaptosome preparations from
the different brain regions, preparations from both motor
cortex and cerebellum showing similar levels of enrich-
Figure 1. Gross cortical atrophy in CLN5 sheep brains. Nissl-stained sections showed marked atrophy of the cortical mantle in affected sheep at
19 months of age, which was more pronounced by 24 months of age. In contrast, the cerebellum and subcortical structures were relatively
spared.
Figure 2. Atrophy of motor cortex in CLN5 sheep brains. Microscopic
comparison of the motor cortex of Nissl-stained sections (shown in
Fig. 1). Upper arrows mark the layer I/II boundary, the middle arrows
indicate layer IV, and the lower arrow marks the layer VI/white matter
boundary. Scale bar 200 lm.
Table 1. Cortical thickness measurements from 24-month-old normal
control and CLN5 Batten sheep brains
Layers
Mean thickness (lm  SEM)*
P value**Normal control CLN5 affected
Cerebellar cortex 502  10 493  11 NS
Motor cortex (I–VI) 1692  45 940  21 ≤0.001
*Measurements from three animals per group and >25 measurements
per brain/region.
**Student’s t test.
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ment (Fig. 5). Thus, it was possible to use standard
synaptosome protocols to generate preparations of synap-
tically enriched tissue from sheep brains, even using sam-
ples that had been frozen and stored.
Conservation of synaptic proteins between
mouse and sheep synaptosomes
Our success in isolating synaptosome preparations from
the cerebellum and motor cortex of sheep brains allowed
us to next ask whether known molecular regulators of
synaptic pathophysiology, previously identified in Droso-
phila and mouse models, were similarly present in
synapses from the sheep brain, and could be identified
using primary antibodies previously used for studies of
the mouse nervous system (Wishart et al. 2012). In these
experiments, we compared levels of eight individual pro-
teins previously shown to be present in mouse synapses,
and whose expression levels were robustly modified in
synapses undergoing degeneration: a-synuclein, calretinin
(Calb2), 20,30-cyclic nucleotide 30 phosphodiesterase
(CNP), cysteine-string protein alpha (CSP-a; DNAJC5),
neurofascin, rho-associated, coiled-coil containing protein
kinase 2 (ROCK2), sirtuin 2 (SIRT2), and ubiquitin pro-
tein ligase E3 component n-recognin 4 (UBR4) (Wishart
et al. 2012). Direct comparison of these proteins in
synaptosome preparations from mice and sheep, using
fluorescent Western blotting, confirmed that all eight pro-
teins were conserved between the two species and were
detectable using the same primary antibodies (Fig. 6).
Figure 3. MRI analyses of CLN5 Batten
sheep brain confirms targeting of the
cortex and sparing of the cerebellum.
Representative MR images of control (A, C,
E, G) and CLN5 sheep (B, D, F, H). Sections
are shown in sagittal (A–B), horizontal (C–
D) and two coronal cuts (E–F and G–H at
the levels marked in A–D). The scale bar is
2 cm. Label abbreviations: Fr frontal lobe;
Pa parietal lobe; Occ occipital lobe; Te
temporal lobe; LV lateral ventricle, Th
thalamus, H hippocampus; Cb cerebellum;
Cd caudate; Pu putamen.
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Region-specific modifications in known
regulators of synaptic stability in CLN5
Batten sheep
Our ability to detect and measure levels of individual pro-
teins implicated in the regulation of synaptic degeneration
(Fig. 6) allowed us to directly test whether molecular path-
ways being instigated in degenerating synapses from the
sheep brain are the same as those previously reported in
the mouse brain. We therefore generated region-specific
synaptosome preparations from the brains of five control
and eight CLN5 Batten disease sheep. Quantitative fluores-
cent Western blotting was used to measure and compare
levels of the eight synaptic proteins previously found to be
conserved in the sheep brain.
Figure 4. Loss of synapses in affected brain regions from CLN5 Batten disease sheep. A. Quantitative fluorescent Western blotting in
preparations of whole tissue revealed relatively stable levels of SV2, a core synaptic protein, in the cerebellum of control and CLN5 sheep. In
contrast, in the motor cortex of CLN5 Batten disease sheep, the levels of SV2 are reduced by 60%, indicating there is severe synapse loss
restricted to this brain area of the Batten sheep. (N = 5 animals, n = 10 distinct tissue samples from control sheep; N = 8, n = 16 from CLN5
sheep; ****P < 0.0001, unpaired two-tailed t-test). B. Representative fluorescent Western blots (N = 5 animals per genotype) showing a
consistent decrease in SV2 levels in the motor cortex of CLN5 Batten disease sheep when compared to controls. Note the relatively stable levels
of SV2 in the cerebellum of CLN5 sheep. Actin was used as loading control.
Figure 5. Characterization of synaptosome preparations from control
and CLN5 Batten disease sheep brains. Representative fluorescent
Western blots showing levels of a core synaptic protein (SV2), a core
nuclear protein (HDAC2) and a loading control (actin) in synaptic (S)
and nonsynaptic (NS) fractions generated from the cerebellum and
motor cortex of control and CLN5 Batten disease sheep brains. Note
the enrichment of synaptic protein and exclusion of nuclear protein in
the synaptic fractions.
Figure 6. Conserved expression and Western blot detection of
synaptic proteins in synaptosome preparations from mice and sheep.
Representative fluorescent Western blots showing levels of eight
synaptic proteins implicated in the regulation of synaptic stability and
degeneration, as well as a loading control (actin), in synaptosome
preparations from mouse and sheep brain. Note how all synaptic
proteins previously identified in mouse synapses were similarly
present, and detectable using the same primary antibodies, in sheep
synapses.
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An initial comparison of protein levels in synaptosomes
generated from the cerebellum (a minimally affected brain
region; see above) revealed no significant differences in
expression levels of any of these proteins in cerebella from
control and CLN5 sheep (Fig. 7A). This analysis con-
firmed that we could repeatedly detect and measure all
eight synaptic proteins across samples from multiple
animals, and also demonstrated that levels of these pro-
teins are relatively stable in areas of the brain from CLN5
Batten disease sheep not grossly affected by neurodegener-
ation.
In striking contrast, a comparison of protein levels in
the motor cortex (a severely affected brain region; see
above) revealed significant differences in the expression of
seven out of the eight proteins examined (Fig. 7B). Sev-
eral proteins were reduced to less than half in CLN5 cor-
tical synapses compared to controls (a-synuclein, CSP-a,
Neurofascin, ROCK2, and SIRT2). In contrast, there was
almost twice as much calretinin in synapses from the
affected motor cortex than from control sheep. Thus,
synaptic proteins previously implicated in synaptic degen-
eration pathways in mice and Drosophila also presented
dynamic modifications to their expression levels in
synapses from neurodegenerating regions from CLN5
Batten disease sheep compared to controls.
Discussion
This study set out to address whether cellular and molec-
ular aspects of synaptic pathophysiology previously identi-
Figure 7. Modified expression levels of synaptic proteins in motor cortex from CLN5 Batten disease sheep. A–B. Levels of the eight synaptic
“degeneration” proteins (actin was used as a loading control) in synaptosome preparations generated from the unaffected cerebellum of control
and CLN5 Batten disease sheep are shown. Data in panel A (N = 5, n = 10 control; N = 8, n = 16 CLN5) are shown as mean  SEM. Statistical
analyses revealed no significant differences (P > 0.05 in t-test) in the level of any protein between control and CLN5 samples. Representative
Western blots from a single experimental run (N = 5 animals per genotype) are shown in panel B. C–D. Levels of the eight synaptic
“degeneration” proteins (actin was used as a loading control) in synaptosome preparations generated from the affected motor cortex of control
and CLN5 Batten sheep are shown. Data in panel C (N = 5, n = 10 control; N = 8, n = 16 CLN5) are shown as mean  SEM. Statistical analyses
revealed significant differences in the levels of seven proteins between control and CLN5 samples (*P < 0.05; **P < 0.01; ****P < 0.0001; in
t-test). Representative Western blots from one experimental run (N = 5 animals per genotype) are shown in panel D.
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fied in Drosophila and mouse models of a range of dis-
eases (including Batten disease), are recapitulated in larger
animal models of neurodegenerative disease. Our initial
findings confirmed the regionally restricted nature of dis-
ruption to synaptic integrity in areas of the brain of
CLN5 sheep undergoing significant neurodegeneration
(e.g. loss of SV2 was observed in the affected motor cor-
tex but not in the spared cerebellum). Previous studies
using mouse and Drosophila models of Batten disease
have revealed that synaptic disruption is intimately linked
to the regional onset of neurodegeneration (Cooper 2010;
Bond et al. 2013), with our findings demonstrating that
the relationship between synaptic pathology and neurode-
generation is likely to be similarly conserved in CLN5
sheep. However, given the symptomatic nature of the
sheep investigated in this study, further studies examining
synaptic changes at pre and early-symptomatic time
points will now be required in order to establish whether
synaptic loss precedes, or occurs concurrently with, gross
neuropathological changes.
Interestingly, in some other forms of Batten disease,
the course of glial activation and subsequent neurodegen-
eration may occur differently in mice compared to large
animals and humans (albeit with inherent difficulties
when comparing across species and different genetic
mutations). For example, cerebellar involvement has been
noted in the PPT1-deficient mouse model of infantile
NCL (Macauley et al. 2009), whereas glial activation and
neurodegeneration generally begins in the upper cortex in
large animal models of Batten disease (best described in
CLN6 sheep (Oswald et al. 2005, 2008)) and human Bat-
ten disease patients, with the cerebellum remaining largely
spared. In contrast, the neuropathological changes we
report here suggest similar regional targeting in CLN5
mice (von Schantz et al. 2009) and sheep.
We also demonstrated the ability to generate synapto-
some preparations from frozen sheep brain samples, and
used this technique to confirm conserved expression of
synaptic proteins between sheep and mouse models of
disease. Finally, we found that molecular pathways previ-
ously found to regulate synaptic pathophysiology in Dro-
sophila and mice were reproduced in synapses from
affected regions of CLN5 sheep brain. Taken together,
these findings suggest that molecular mechanisms under-
lying synaptic pathophysiology are conserved in an estab-
lished sheep model of Batten disease, demonstrating the
importance of studies utilizing large animal models for
the identification, development, and testing of therapies
aimed at delaying or halting synaptic pathology across a
range of neurodegenerative conditions.
The demonstration of synaptic involvement in neu-
ropathological pathways activated in affected brain
regions from CLN5 sheep provides significant additional
experimental support for the hypothesis that synapses
play an important role in the progression of neurodegen-
eration in the NCLs (Virmani et al. 2005; Luiro et al.
2006; Partanen et al. 2008; Kielar et al. 2009; Koch et al.
2011). The additional support gained from analyses of
this large animal model indicates that the synaptic pheno-
types previously reported in a range of in vivo and
in vitro studies of NCLs utilizing lower organisms (Vir-
mani et al. 2005; Luiro et al. 2006; Partanen et al. 2008;
Kielar et al. 2009; Koch et al. 2011) are a conserved fea-
ture of these diseases applicable to all animal models as
well as human patients. This finding places the NCLs
alongside a range of other neurodegenerative diseases
where synaptic pathology is a major focal point for dis-
ease instigation and progression (including Alzheimer’s
disease, Huntington’s disease and motor neuron disease
(Wishart et al. 2006)). Moreover, the finding that molec-
ular mechanisms underlying synaptic pathophysiology are
conserved across several different neurodegenerative con-
ditions (Wishart et al. 2012) suggests that studies examin-
ing mechanisms of synaptic pathology in one condition
(such as the NCLs) may also have applicability to other
related neurodegenerative conditions.
Alongside the finding that cellular aspects of synaptic
pathology were conserved between large and small animal
models of the NCLs, the demonstration that molecular
regulation of synaptic pathophysiology is also conserved
between species is likely to be of particular importance
for future studies, using animal models to design and test
synaptically targeted therapies for humans. For example,
levels of synaptic a-synuclein were significantly reduced in
the motor cortex, but not the cerebellum, of CLN5 sheep.
a-Synuclein is known to regulate synaptic stability and
function in a variety of other animal model systems,
including mouse neurons (Volpicelli-Daley et al. 2011;
Rockenstein et al. 2014). Changes in a-synuclein have
been reported in many studies of Batten disease, particu-
larly in CLN1 and CLN10 (cathepsin D) deficient mice
(Cullen et al. 2009; Blom et al. 2013; Koch et al. 2013)
and recently in Atp13a2-deficient (CLN12) mice
(Schultheis et al. 2013). a-Synuclein is known to modu-
late synaptic pathology in mice, at least in part through
interactions with another synaptic protein, CSP-a (Chan-
dra et al. 2005). Mutations in CSP-a lead to a dominant
adult form of NCL, Kuf’s disease (CLN4 (Noskova et al.
2011; Benitez et al. 2011)), and levels of CSP-a were also
significantly modified in synapses from affected regions of
CLN5 sheep brain. Similar links have been established for
many of the other proteins we examined in our study,
where previous data from a combined mouse/Drosophila
study identified them as potential regulators of synaptic
and axonal degeneration (Wishart et al. 2012). Thus,
many of the molecular regulators of synaptic pathophysi-
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ology identified in studies using lower organisms appear
to be conserved in the sheep model of CLN5 Batten dis-
ease, establishing a clear path from small animal to large
animal to human patients with neurodegenerative disease.
Given the considerable overlap in the molecular charac-
teristics of synaptic pathology between sheep and small
animal models, it follows that therapies designed to target
these pathways, shown to be affective in small animal
models, could be taken forward into sheep models, better
placed to replicate the size- and age-related aspects of the
human nervous system (Aigner et al. 2010; Morton and
Howland 2013; Pouladi et al. 2013; Dolezalova et al.
2014). Demonstration of therapeutic effectiveness of a
given treatment in a large animal model would provide a
robust basis for subsequent translation to cohorts of
human patients. This approach is likely to reduce the
financial waste associated with failed clinical trials based
on data from small animal models (Perrin 2014), and
speed up the identification of the best candidate therapies
for human patients.
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